Stocks

MindMed (MMEDF) uplists to NASDAQ

MindMed (MMEDF) uplists to NASDAQ

MindMed (MMED) shares surged to almost $3 per share. The company announced that it will uplist and begin trading on NASDAQ on Tuesday April 27.

The company said it will retain its listing on the Neo Exchange under the symbol “MMED”. The new symbol that will begin trading on April 27 is MNMD.

The listing of our stock on the Nasdaq represents a significant milestone in our growth as a publicly-traded company, we believe this listing will increase our visibility in the marketplace, improve liquidity, broaden and diversify our shareholder base, and ultimately enhance long-term shareholder value. I would like to thank our employees, management, directors and our many collaborators for their hard work in making MindMed a member of the Nasdaq exchange, an important step that will help facilitate our mission to discover, develop and deploy psychedelic inspired medicines and therapies to address addiction and mental illness.

J.R. Rahn, CEO and Co-Founder of MindMed

It’s also good to note that the company is backed by Shark Tank’s Kevin O’Leary.

According to MotelyFool, here’s what Kevin had to say back in January 2021:

Kevin O’Leary: I never participated in cannabis because when I wanted to and I was shown so many marijuana steals, all kinds of them, my compliance department, because I’m the chairman of O’Shares, I’m chairman of Beanstox and I have other investments in Fintech. I have a pretty big compliance department because we’re regulated. They were never comfortable with the fact that it was a schedule one narcotic and not all states have made it legal. Then you’re subject to the RICO statute it’s a complicated legal concept, but there was a lot of hope that the House would approve cannabis. It’s not going to happen. There’s too many lobby groups and in states like Texas and Florida, it’s just not going to be legalized, so I never participated in that. A couple of years ago, this is a good example of venture investing, there is a really interesting crypto community in Miami, and they generally meet on Saturdays for lunch at the Soho club, the back table. Some of the smartest guys in crypto, and if you want to get hip to what’s going on in crypto, you attend one of these lunches. I attended many of them. There was one deal that I really wanted to invest in. It was going to be a crypto REIT, where we set it up in Iceland and our energy costs to mine were going to be next to nothing because we didn’t have to air condition NVIDIA chips, which really heat up and you’ve got to spend a lot of money air conditioning. I took it back to my compliance department and she said to me, “Are you out of your (beep) mind? We can’t touch Bitcoin. It is not a regulated asset.”

That one went away, but at that lunch, and this is the serendipitous nature of investment, this guy called JR Rahn, he was a crypto guy at the time, said, “Look, if you think that’s nuts, I have something I want to talk to you about. I want you to fund me to bring LSD, MDA, psilocybin mushrooms as medicine.” I said, “Are you crazy? That stuff is illegal.” He said, “Yes, it is. But in the 50s and 60s they were researching it as medicine in microdosing and having really interesting outcomes. I want to go to the FDA and create a company that goes through clinical trials.” I thought that was brilliant, because I’m a kid with dyslexia. So all those medicines, we haven’t had new medicines for mental illness in 37 years. I’ve heard the stories of microdosing in Silicon Valley. I said, “You know what?”, I went back to my compliance people and I said, “Listen, if you thought Bitcoin was crazy, listen to this.” All she said me was, “Is this FDA approved?” I said, “Not yet, but they’re going to the FDA for trials.” She said,” I have no problem. Go nuts.”

I became a very early investor in MindMed, I became an advocate for the whole sector. I’m a spokesperson for it, I’m a big believer in these medicines, and lo and behold, JR’s company is now a $2 billion market cap. I’m one of the early seed investors. It’s the best investment I’ve made in decades. I think it’s just the beginning of the game. When you invest in biotech, you want the largest number of molecules and the most trials because you don’t know the outcome in any of it. Either it’s binary, either it’s a loser, it’s a zero, or it’s a spectacular outcome. That’s the nature of biotech investment. But if you’re only betting on one molecule, you have huge risk. JR has got multiple molecules, multiple trials, multiple countries. That’s his plan. He’s quickly become the leader in this space. He is the guy. I’m a huge fan of that. By the way, on that one, I remember Alex, remember the guy who said rips flesh like a weasel in due diligence, I sent Alex after JR. I said, “Alex, tell me if this is for real.” He came back and he said, “Not only am I borrowing Mike the dough you owe on this deal, I’m going to put my own dough in.” That to me was like, whoa, what’s going on here? Alex was also a big participant in the seeding of MindMed.